SCHEDULE: Immunome Investor Stake Dips Below 5% After Equity Offering
Beneficial Ownership Update
Enavate Sciences and Immunome Aggregator report their beneficial ownership in Immunome, Inc. common stock has been diluted to 4.3% following a recent public equity offering.
Summary
- This Amendment No. 2 to Schedule 13D updates previous filings from October 12, 2023, and February 4, 2025.
- The amendment reports a dilution of beneficial ownership by Enavate Sciences GP, LLC and Immunome Aggregator, LP in Immunome, Inc. common stock.
- The dilution is a result of an increase in the number of outstanding shares of Immunome, Inc. and not due to any acquisition or disposition of securities by the reporting entities.
- As of December 18, 2025, the reporting entities collectively beneficially own 4,768,583 shares, representing 4.3% of Immunome, Inc.'s common stock.
- This percentage is calculated based on 91,710,277 shares outstanding as of November 3, 2025, plus an additional 18,625,000 shares issued in a public offering that closed on December 18, 2025.
- The reporting entities ceased to be beneficial owners of more than five percent of Immunome, Inc.'s common stock on December 18, 2025.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual report of a change in beneficial ownership due to dilution from a public offering. It does not convey positive or negative sentiment from the reporting entities' perspective, beyond the fact of reduced ownership. The capital raise itself is generally positive for the issuer, but the filing focuses on the reporting entities' stake.
Positives
- Immunome, Inc. successfully completed a public offering of equity securities, issuing 18,625,000 shares, which closed on December 18, 2025, indicating successful capital formation for the issuer.
Negatives
- The reporting entities' beneficial ownership in Immunome, Inc. has been diluted below the 5% threshold, potentially reducing their influence.
Future Outlook
N/A
Industry Context
N/A
Stakeholder Impact
- Shareholders (Reporting Entities): Reduced proportional ownership and potential influence in Immunome, Inc.
- Shareholders (General): Increased number of outstanding shares due to the public offering.
- Immunome, Inc.: Successful capital raise, providing additional funding for operations or strategic initiatives.
Key Dates
| Date | Description |
|---|---|
| October 12, 2023 | Original Schedule 13D filed with the SEC. |
| February 4, 2025 | Previous amendment (Schedule 13D/A) filed with the SEC. |
| November 3, 2025 | Date as of which 91,710,277 shares of common stock were outstanding, as reported in the Issuer's Form 10-Q. |
| November 6, 2025 | Issuer's Quarterly Report on Form 10-Q filed with the SEC. |
| December 16, 2025 | Date of the Issuer's prospectus supplement for the public offering. |
| December 17, 2025 | Issuer's prospectus supplement filed with the SEC. |
| December 18, 2025 | Public offering of equity securities closed; Reporting Entities ceased to be beneficial owners of more than five percent of common stock. |
| December 22, 2025 | Date of signature for this Amendment No. 2 filing. |
Keywords
Immunome, Enavate Sciences, Immunome Aggregator, Schedule 13D, beneficial ownership, equity offering, dilution, common stock, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.